These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 766946)
1. A phase II study of intravenously- administered methyl CCNU in the treatment of advanced sarcomas. Chang P; Levine MA; Wiernik PH; Walker MD Cancer; 1976 Feb; 37(2):615-9. PubMed ID: 766946 [TBL] [Abstract][Full Text] [Related]
2. Comparison of methyl-CCNU and CCNU in patients with advanced forms of Hodgkin's disease, lymphosarcoma nad reticulum cell sarcoma. Maurice P; Glidewell O; Jacquillat C; Silver RT; Carey R; Pas AT; Cornell CJ; Burningham RA; Nissen NI; Holland JF Cancer; 1978 May; 41(5):1658-63. PubMed ID: 348294 [TBL] [Abstract][Full Text] [Related]
3. Methyl-CCNU versus methyl-CCNU and 5-fluorouracil in carcinoma of the large bowel. Posey LE; Morgan LR Cancer Treat Rep; 1977 Nov; 61(8):1453-8. PubMed ID: 922750 [TBL] [Abstract][Full Text] [Related]
4. Methyl CCNU and adriamycin for patients with metastatic sarcomas: a Southwest Oncology Group study. Rivkin SE; Gottlieb JA; Thigpen T; El Mawla NG; Saiki J; Dixon DO Cancer; 1980 Aug; 46(3):446-51. PubMed ID: 7397620 [TBL] [Abstract][Full Text] [Related]
5. Combination with 5-fluorouracil, methyl-CCNU and beta-2-deoxythioguanosine in advanced colo-rectal adenocarcinoma. Cedermark BJ; Kaufman JH; Douglass HO; Mittelman A Clin Oncol; 1977 Mar; 3(1):27-31. PubMed ID: 862274 [No Abstract] [Full Text] [Related]
6. Methyl-CCNU for patients with previously treated metastatic neuroblastoma--a phase II study. Evans AE; Bernstein I; Finklestein J; Klemperer M; Leikin S; Weiner JM; Hammond GD Cancer Treat Rep; 1977; 61(1):83-5. PubMed ID: 324623 [No Abstract] [Full Text] [Related]
7. [The combination methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in the treatment of advanced colo-rectal adenocarcinoma]. Togni P; Sessa C; Varini M; Cavalli F Schweiz Med Wochenschr; 1982 Jun; 112(26):930-3. PubMed ID: 6214002 [TBL] [Abstract][Full Text] [Related]
8. Iv methyl-CCNU and ftorafur with or without methanol-extracted residue of BCG for metastatic adenocarcinoma of the colon. Diggs CH; Wiernik PH; Smyth AC Cancer Treat Rep; 1977 Nov; 61(8):1581-3. PubMed ID: 336200 [No Abstract] [Full Text] [Related]
9. Phase I trial of combination methotrexate and methyl-CCNU in patients with advanced neoplastic diseases. Lehane DE; Lane M; Tranum B; Costanzi J; Padilla F Cancer Treat Rep; 1977 Aug; 61(5):889-91. PubMed ID: 329982 [No Abstract] [Full Text] [Related]
10. Phase II trial of cisplatin (CPDD) in previously treated patients with advanced soft tissue sarcoma. Brenner J; Magill GB; Sordillo PP; Cheng EW; Yagoda A Cancer; 1982 Nov; 50(10):2031-3. PubMed ID: 6889911 [TBL] [Abstract][Full Text] [Related]
11. A phase II evaluation of methyl CCNU and actinomycin D in the treatment of advanced sarcomas in adults. Yap BS; Benjamin RS; Burgess MA; Murphy WK; Sinkovics JG; Bodey GP Cancer; 1981 Jun; 47(12):2807-9. PubMed ID: 7260872 [TBL] [Abstract][Full Text] [Related]
12. Phase II trial of ftorafur with mitomycin C versus ftorafur with methyl-CCNU in untreated colorectal cancer. Buroker T; Wojtaszak B; Dindogru A; DeMattia M; Baker L; Groth C; Vaitkevicius VK Cancer Treat Rep; 1978 May; 62(5):689-92. PubMed ID: 350398 [TBL] [Abstract][Full Text] [Related]
13. Treatment of advanced colorectal cancer with methyl-CCNU plus 5-day 5-fluorouracil infusion. Kane RC; Cashdollar MR; Bernath AM Cancer Treat Rep; 1978 Oct; 62(10):1521-5. PubMed ID: 709554 [TBL] [Abstract][Full Text] [Related]
14. Phase II study of mitolactol and semustine combination chemotherapy for advanced malignant melanoma. Creagan ET; Ahmann DL; Schutt AJ; Green SJ Cancer Treat Rep; 1982 Jun; 66(6):1425-6. PubMed ID: 7083244 [TBL] [Abstract][Full Text] [Related]
15. A comparative clinical trial evaluating the combination of adriamycin, DTIC, and vincristine, the combination of actinomycin D, cyclophosphamide, and vincristine, and a single agent, methyl-CCNU, in advanced sarcomas. Creagan ET; Hahn RG; Ahmann DL; Edmonson JH; Bisel HF; Eagan RT Cancer Treat Rep; 1976 Sep; 60(9):1385-7. PubMed ID: 189922 [No Abstract] [Full Text] [Related]
16. Phase I evaluation of semustine in a weekly schedule. Koller CA; Schwalm D; Liepman M; Natale RB; Wheeler RH Cancer Treat Rep; 1983 Jun; 67(6):579-81. PubMed ID: 6861164 [TBL] [Abstract][Full Text] [Related]
17. Methyl-CCNU in malignant melanoma--a divided dose schedule of administration. Wittes RE; Hong WK; Gatchell L; Krakoff IH; Golbey RB Oncology; 1977; 34(1):45-6. PubMed ID: 865760 [TBL] [Abstract][Full Text] [Related]
18. Iv methyl-CCNU, VM-26, and cranial irradiation in therapy for malignant brain tumors. Gutin PH; Walker MD Cancer Treat Rep; 1977 Dec; 61(9):1715-7. PubMed ID: 597821 [No Abstract] [Full Text] [Related]
19. The superiority of CCNU in the treatment of advanced Hodgkin's disease: Cancer and Leukemia Group B Study. Hansen HH; Selawry OS; Pajak TF; Spurr CL; Falkson G; Brunner K; Cuttner J; Nissen NI; Holland JF Cancer; 1981 Jan; 47(1):14-8. PubMed ID: 7006789 [TBL] [Abstract][Full Text] [Related]
20. Results with methyl-CCNU and DTIC in metastatic melanoma. Costanza ME; Nathanson L; Schoenfeld D; Wolter J; Colsky J; Regelson W; Cunningham T; Sedransk N Cancer; 1977 Sep; 40(3):1010-5. PubMed ID: 332319 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]